CD274 and neoplasm: Intervention: MEDI0457 (DNA immunotherapy targeting HPV16/18 E6/E7 with IL-12 encoding plasmids) in combination with Durvalumab for PD-1/PD-L1 blockade Key results: Durable antigen-specific peripheral and tumor immune responses.